The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement ...

Cartesian Therapeutics, Inc. RNAC stock is up on Tuesday as the company is announcing a strategic licensing agreement with WestGene Biopharma. The clinical-stage biopharmaceutical company is focused ...

-- In cohort of three patients intended to test safety, all patients showed full-class improvement in the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification and substantial ...

Just to go ahead and give everyone a quick refresher, CAR-T treatment aims to reengineer a patient’s T-cells so that they will eliminate harmful B-cells that cause all sorts of problems. To this day, ...

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Tuesday revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, lead cell therapy candidate, in participants with generalized ...

Cartesian Growth Corporation IV (the 'Company”) announced today the pricing of its initial public offering of 25,000,000 units, at a price of $10.00 per unit. The units are expected to commence ...

Detailed price information for Cartesian Therapeutics Inc (RNAC-Q) from The Globe and Mail including charting and trades.

Cartesian Growth Corp. IV stock grades by Barron's. View CGCFU fundamental and sentiment analysis powered by MarketGrader.